Eurofins Scientific SE · EURONEXT:ERF
Eurofins Scientific — Investor Day (November 2023)
58 slides from Eurofins Scientific's investor day presentation, Nov 9, 2023
Slide 1: 2023 North American Investor Day
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Eurofins: The World Leader in Testing for Life
Eurofins: The World Leader in Testing for Life Key Figures 36 years of value creation • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed ca. 900 laboratories 450,000,000+ • Competitive advantages based on tests performed each ye
Slide 4: Eurofins remains very confident in its objectives for organic growth and M&A
Eurofins remains very confident in its objectives for organic growth and M&A Revenue bridge (2023E to 2027E) Approaching organic M&A €10bn growth organic M&A growth organic M&A growth €6.45bn organic M&A to growth €6.55bn • Continued strong growth outlook in all Eurofins activities average • Increas
Slide 5: Continued strong secular growth outlook in all Eurofins activities
Continued strong secular growth outlook in all Eurofins activities 2023-2027 objective: 6.5% p.a. average organic growth Revenue share Organic growth Activities in H1 2023 Growth drivers outlook • Rising awareness and demand for food safety & quality • Food and Feed Testing and contamination & pollu
Slide 6: Solid margin performances in North America and Rest of the World, while improvement needed in Europe
Solid margin performances in North America and Rest of the World, while improvement needed in Europe Europe North America Rest of the World 40% 40% 40% 30% 30% 30% 20% 20% 20% 10% 10% 10% 0% 0% 0% 1 2 2 1 2 2 1 2019 2020 2021 2022 2023E … 2019 2020 2021 2022 2023E … 2019 2020 2 2021 2 2022 2023E … R
Slide 7: Eurofins is developing proprietary automation technologies
Eurofins is developing proprietary automation technologies and starting to deploy them across its global network Bespoke modular automation platform Attractive financial profile Multi-year investments underway • Significant OpEx for development • Part of CapEx for growth and efficiency Example Conta
Slide 8: Eurofins' proprietary IT solution offers more for clients and costs less
Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro
Slide 9: Disciplined capital allocation has been the foundation of profitable expansion
Disciplined capital allocation has been the foundation of the profitable expansion of the Core Business1 12 1 Core Business Revenue (€bn) 10 8 COVID-19 Revenue (€bn) 0.6 6 1.4 0.8 Approaching 10 4 6.45 €10bn 6.1 to 4.6 4.6 5.3 6.55 2 3.0 3.8 2.0 2.5 0 1.0 1.2 1.4 2 2012 2013 2014 2015 2016 2017 2018
Slide 10: Eurofins remains committed to its prudent capital allocation strategy
Eurofins remains committed to its prudent capital allocation strategy centred on growth investments1 Cash flow generation (2019-2022) Investment allocation 2019-2022 (2019-2022) % of sales Maintenance capex Assume ~2.5% of sales Sales €23.4bn Net cash provided by operating activities €4.5bn 19.4% Ac
Slide 11: Investments in start-ups are integral to long-term growth and value creation
Investments in start-ups are integral to long-term growth and value creation Long track record Strategic rationale Contributions by start-ups in FY 2022 Number of start-ups created Complements M&A strategy: • When acquisitions are too expensive or Organic growth contribution Programme Total Per year
Slide 12: Site ownership has attractive financial fundamentals
Site ownership has attractive financial fundamentals Benefits Examples • Estimated rent savings of €68m1 in FY 2022 from owned sites 1 Savings • Estimated yield on rent savings from owned sites of 11% (based on net book value at end of 2022 of €635m) • Lower operating costs from investment in renewa
Slide 13: Very healthy leverage and long-term debt maturity profile
Very healthy leverage and long-term debt maturity profile Leverage1 Debt maturity profile3 (€m) Key Highlights • Net debt decreased from €3,245 at Cash3 the end of FY 2019 to €2,588m2 at 3.2x the end H1 2023 Hybrid (1st call) Schuldschein • 90% of borrowings at fixed rates Eurobond 3 • Stable financ
Slide 14: Our mid-term objectives & drivers
Our mid-term objectives & drivers (€m) FY 2023 Mid-term objectives & drivers FY 2027 • Average +6.5% organic growth p.a. Revenues €6.45bn – €6.55bn • Potential average revenues from acquisitions of €250m p.a. Approaching €10bn • Organic growth and acquisitions • Align pricing to cost inflation Adj.
Slide 15: Summary
Summary Continued strong secular growth outlook in all Eurofins activities Long-term track record of disciplined capital allocation to drive growth, productivity, margin expansion and Return on Capital Employed Market leadership Ongoing investment to develop and deploy sector-leading proprietary IT
Slide 16: BioPharma Services
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 17: BioPharma Services – Comprehensive Global Offering
BioPharma Services – Comprehensive Global Offering Clinical Development Pre-clinical / BioPharma PSS1 (Central & Agroscience Genomics Discovery Early Product Insourcing Laboratory/ Manufacturing Services Development Testing Solutions Bioanalytical) (CDMO) 20 countries US 40 sites 287 projects US US
Slide 18: Leading Global BioPharma Network
Leading Global BioPharma Network ~190,000 m2 Leader in significant markets ~130,000 ~5,000 • Global leader in BioPharma Product Testing m2 ~6,000 employees employees • Global leader in Discovery Pharmacology Services 82 • Global leader in Agroscience CRO Services laboratories 32 Europe laboratories
Slide 19: BioPharma Services Evolution
BioPharma Services Evolution Started Select milestones / acquisitions Market position today 2011: Global infrastructure established (US, Among top 5 global players 2001 Central Laboratory / Bioanalytical Acquisitions: Netherlands, Singapore, China, India) 2005 Genomic Services Acquisitions: Among to
Slide 20: Clients & Peers
Clients & Peers Major Biopharma companies Innovative biotech Example clients Clients1 + regional & local players Typical contractual ➢ Product Testing: annual master service agreements relationship: ➢ Research & Development Services: project-based agreements Peers + regional & local competitors CONF
Slide 21: Market Update
Market Update CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 21
Slide 22: State of BioPharma Industry Funding
State of BioPharma Industry Funding BioPharma Funding1 ($bn) BioPharma Firepower ($bn) (IPOs, Follow-ons, Private and Public/Other) • Biotech funding has normalised in 2022-2023E at levels on par with best 1,422 135 118 levels pre-COVID, as investor willingness to fund promising 68 67 candidates rem
Slide 23: BioPharma Job Openings
BioPharma Job Openings • Despite high-profile layoffs, overall demand for talent has remained robust despite the normalisation of biopharma funding • Appetite for life sciences talent remains strong, driven by well-funded companies continuing to advance their R&D pipelines • Expect geopolitics to dr
Slide 24: R&D Spend Evolution
R&D Spend Evolution Worldwide Total Pharmaceutical R&D Spend ($bn)1 Market drivers R&D spend continues to grow substantially, driven by 350 intensity & speed of innovation 289 296 302 • Increased focus on biologics vs. small molecules 300 281 262 272 = increasing amounts spent per drug 249 250 244 •
Slide 25: Large Market Opportunities
Large Market Opportunities Novel innovations1 Chemicals Biologics Cell and gene therapies Opportunities for Eurofins Description / Complexity2 Increasing complexity in testing and clinical Altering of genetic material trials Traditional, biomarkers, Traditional, biomarkers, genomics, Evidence / Endp
Slide 26: Delivering Value to our Clients
Delivering Value to our Clients CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 26
Slide 27: Strategic expansion of the BioPharma network
Strategic expansion of the BioPharma network Expanding capacity across our areas of activity Net floor area (k m2) for BioPharma BioPharma Discovery Genomic CDMO Services Change Product Testing Services Services 400 2018-2022 Dungarvan, IE 350 • Significant Glostrup, DK Homburg, DE investments in fi
Slide 28: DiscoveryAI: Accelerating drug discovery through artificial intelligence
DiscoveryAI™ Accelerating drug discovery through artificial intelligence DiscoveryAITM can be used to add value throughout the early drug discovery DiscoveryAI potential stages Drug-to-market time: reduced by >20% Predictive accuracy: 75% • Integrated into all Eurofins Integrated Drug Discovery proj
Slide 29: DiscoveryOne: Enabling Drug Discovery Through Integration
DiscoveryOne™ Enabling Drug Discovery Through the Integration of Our Testing and Consulting Capabilities 10 Eurofins Companies Integrated service offering Strong Growth >5X revenues Acquired 2013 Biotherapeutics & Acquired 2004 Acquired 2012 Chemistry Cell/Gene Therapy Discovery & Development Soluti
Slide 30: Established leading player in Cell and Gene Therapy
Established leading player in Cell and Gene Therapy with comprehensive client offering and >10 years of experience Successful and long track Supported the development of: record with Cell and Gene • 16 of 24 FDA-approved1 Cell and Gene Therapy Products Therapies (C>) • All 6 CAR-T therapies Eurofi
Slide 31: Case study: global CAR-T Cell Therapy partnership
Case study: global CAR-T Cell Therapy partnership End to end support from development through commercial Strategic use of Eurofins Service models Global Footprint • FFS (Fee For Service) – tactical needs (raw materials, micro, cell banking) Multiple Service Models Facilitating Data Digitization • FT
Slide 32: Eurofins' proprietary IT solution offers more for clients and costs less
Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro
Slide 33: Differentiators
Differentiators One-stop-service provider with a local, tailored approach to clients; Decentralised & Agile Innovative & R&D Driven Solutions: Specialty solutions for Biologics Customer Support larger clients across multiple countries and continents around the world trust Differentiated delivery mod
Slide 34: CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use
CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 3434
Slide 35: Food & Feed Testing North American Laboratories Network
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 36: Eurofins Food & Feed best-in-class hub and spoke network in North America
Eurofins Food & Feed has built and operates the best-in- class hub and spoke network in North America HUB LABS Des Moines, IA Madison, WI Madison, WI New Orleans, LA Toronto, ON Toronto, ON Los Angeles, CA Minneapolis, MN Madison, WI SPOKE LABS Atlanta, GA Gordon, NE Philadelphia, PA Battle Creek, M
Slide 37: North American 3rd party food testing is a ~$2.5B market with tailwinds
North American 3rd party food testing is a ~$2.5 B market with tailwinds that accelerated through the pandemic NA 3rd Party Testing & Services $ Billion est 2022 Relevant market trends 2.5 • Supplement/Nutraceutical production 10+% CAGR with desire for healthier, functional foods, sports nutrition i
Slide 38: Competitors
Eurofins is the clear leader in North America because of our differentiated breadth, science and reputation Competitors Eurofins’ market share1 Small local players1 Other major players #1 share ~2/3 share Chemistry Microbiology Services Science & Reputation Contaminants Nearly 100 years of expertise
Slide 39: Our market position is strong because of many nodes in our network
Our market position is strong because of many “nodes” in our network and support systems are difficult to copy General micro Difficult-to-copy (across 13+ network node Specialty U.S. regions) GMO testing microbiology Common Lab IT Lab System Single nodes Inter-business price list pricing Allergens S
Slide 40: NA Food & Feed labs take far less capex and have much faster break-even
NA Food & Feed labs take far less capex and have much faster break-even than our 2017/18 start-up program Madison, WI Hub Des Moines Hub Addition • Opened: January 2021 • Opened: August 2023 • Net floor area: 10,000 sqm • Net floor area: 650 sqm • Incremental build on owned • Build cost: ~$40m • Bui
Slide 41: We expect continued above-market growth with new speed
We expect continued above-market growth with new speed, and quality standards hard to match without our scale Performance area One-stop shop • Hyper local microbiology laboratories (e.g. meat/produce/supplements) coverage • Niche chemistry: botanical genetics, new contaminants (PFAS) Only in-class •
Slide 42: Summary
Summary Operate best-in-class Food & Feed Testing network in N. America Provide most comprehensive offering Market Deliver above-market growth from hard-to-copy network leadership Accelerate sales from start-up programs, prudent M&A Disrupt industry even further, setting new standards for food testi
Slide 43: Eurofins Environment Testing US
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 44: U.S. Market Overview
U.S. Market Overview CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 44
Slide 45: Macro Trends – ESG Driven Decoupling from GDP
Macro Trends – ESG Driven Decoupling from GDP ANNUAL GROWTH IN THE ENVIRONMENTAL INDUSTRY 2000 -2024 9% Environment sector growth expected above GDP driven by increasing regulations, social awareness of environmental hazards and demand for sophisticated testing 6% 3% 0% 00 01 02 03 04 05 06 07 08 09
Slide 46: U.S. Environment Market Overview
U.S. Environment Market Overview Env. Sectors Env. Services Env. Testing Eurofins Env. Testing US $39.2 $76.8 37% $15.5 $501B 48% $239B ~$2.1B (Testing ~1% of services) (Testing ~5% of Consulting & Engineering) $2.1 15% $105 Services Wastewater Treatment Works (WWTW) Analytical >50% of Market yet to
Slide 47: Regulatory/Political Drivers
Regulatory/Political Drivers Overview U.S. EPA Budget ($B) $10.1 • The US is estimated to spend $150B+ annually $9.6 for ‘Environmental Protection’ – (2% of GDP) $9.1 $9.2 • Drinking Water and Wastewater spend over the next 20 years is estimated to be ~$750B 2020 2021 2022 2023 Bipartisan Infrastruc
Slide 48: PFAS Case Study
PFAS Case Study CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 48
Slide 49: PFAS in the U.S.
PFAS in the U.S. 57,000 Presumptive PFAS Contaminated Sites Occurrence Data • At least 45% of the US tap water is estimated to have one or more types of PFAS contamination. • PFOA and PFOS found in many surface water bodies at several folds higher than the US EPA health advisory levels of 4ng/L. • A
Slide 50: PFAS… Not Just an Environmental Issue
PFAS… Not Just an Environmental Issue… (But all Require Testing) Environmental Products Food Biomonitoring PFAS Regulated Across: PFAS Bans Affecting: Research & Litigation: Research & Litigation Drinking Water, Non-Potable Food Contact Materials, Food Contact Materials CDC, EPA, & Belgium led Water
Slide 51: Evolution of PFAS Regulatory Environment
Evolution of PFAS Regulatory Environment U.S. EU • Sep 2022: EPA proposed designation of PFOA & PFOS as hazardous substances under CERCLA • Dec 2020: EU Directive states that technical guidelines for PFAS monitoring should be • March 2023: EPA proposed national drinking water established, with the i
Slide 52: Eurofins Environment Testing in the U.S.
Eurofins Environment Testing in the U.S. CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 52
Slide 53: Eurofins Environment Testing U.S.
Eurofins Environment Testing U.S. 67 Laboratory Locations ~3,000 Staff (2022) 5M Samples (2022 actual) 550+ Accreditations & Certifications CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an au
Slide 54: Geographic Orientation with Specialty and Drinking Water
Eurofins Environment Testing U.S. Geographic Orientation with Specialty and Drinking Water Hub & Spoke Model Specialty Services* Sacramento (x2) Knoxville Lancaster St. Louis Burlington Denver Drinking Water Los Angeles South Bend Orlando Built Environment Distributed Model CONFIDENTIALAND PROPRIETA
Slide 55: IT Applications – Development Priorities
IT Applications – Development Priorities Micro Automation & Data Self Applications AI Visualization Service More agile and mobile Allow users to focus on Provide more metrics and Give clients more control applications to allow for the human element and dashboards to facilitate over their samples bet
Slide 56: Strategic Imperatives & Enablers
Strategic Imperatives & Enablers Productivity Robotics, Automation, Waste Reduction Technology Detection limits, compounds, matrices, productivity & efficiency People Investment in leaders and development of staff Service On-boarding, data quality turnaround time, testing solutions, digitalization E
Slide 57: Appendix
Appendix CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 57
Slide 58: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor